Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD and MAD Study of ALZ-507 in Healthy Participants
NCT07824271Phase 1Recruiting
- Sponsor
- Alzheon, Inc.
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALZ-507 in Alzheimer's disease (AD) (2 arms), sponsored by Alzheon, Inc. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Mar 2026; status: recruiting.
02
Drugs
ALZ-507
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07824271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824271.